Mycophenolate mofetil treatment of crescentic Henoch-Schönlein nephritis with IgA depositions.
Mycophenolate mofetil (MMF) is considered to be a promising therapeutic agent in primary glomerulonephritis but there are no data on the use of MMF in Henoch-Schönlein nephritis (HSN). Herein we report the first adult crescentic HSN patient in whom long-term complete remission was achieved after MMF therapy.
Dede
Fatih
F
Department of Nephrology, Ankara Numune Training and Research Hospital, Ankara, Turkey. fatded@yahoo.com
Onec
Birgul
B
Ayli
Deniz
D
Gonul
Ipek Isik
II
Onec
Kursad
K
D000328:Adult; D001706:Biopsy; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D005922:Glomerulonephritis, IGA / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D006801:Humans; D011695:IgA Vasculitis / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007668:Kidney / Q000473:pathology; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011355:Prodrugs; D012074:Remission Induction / Q000379:methods
D007166:Immunosuppressive Agents; D011355:Prodrugs; D009173:Mycophenolic Acid